(1) Publication number:

0 175 617 A3

12)

EUROPEAN PATENT APPLICATION

21) Application number: **85401776.1**

(51) Int. Cl.4: A 61 K 39/395

22 Date of filing: 13.09.85

30 Priority: 13.09.84 US 650754 13.09.84 US 650375


- Date of publication of application: 26.03.86

 Bulletin 86/13
- Designated Contracting States: AT BE CH DE FR GB IT LI LU NL SE
- Bate of deferred publication of search report: 15.06.88 Bulletin 88/24

- Applicant: CYTOGEN CORPORATION, 201 College Road East Forrestal Research Center, Princeton New Jersey 08540 (US)
- Inventor: Goers, John Walter, 5200 Dolores Street,
 Atascadero California (US)
 Inventor: Lee, Chyl, 1347 Ute Road, New Brunswick New
 Jersey (US)
 Inventor: Slegel, Richard Charles, 117 Whiton Road,
 Neschanic Station New Jersey (US)
 Inventor: McKearn, Thomas Joseph, R.D. No. 3 Box 119,
 New Hope Pennsylvania (US)
 Inventor: King, Hurley Dalton, 1688-B Bluebird Drive,
 Yardley Pennsylvania (US)
 Inventor: Coughlin, Daniel James, 37-07 Hunters,
 Plainsboro New Jersey (US)
 Inventor: Rodwell, John Dennis, 430 Ramsey Road,
 Yardley Pennsylvania (US)
 Inventor: Alvarez, Vernon Leon, 187 Rice Drive,
- Morrisville Pennsylvania (US)

 Representative: Warcoln, Jacques et al, Cabinet Régimbeau 26, avenue Kléber, F-75116 Paris (FR)
- Antibody-therapeutic agent conjugates.
- 57 This invention relates to antibody-therapeutic agent conjugates having a therapeutic agent covalently attached to an antibody or antibody fragment. Also described are methods for intermediates in the preparation of antibody conjugates. Therapeutic in vivo methods utilizing such antibody-therapeutic agent conjugates are described. Additionally novel photosensitizers suitable for use in preparing antibody-therapeutic agents are also described.

EP 0 175 617 A3





EPO Form 1505.1. 03.82

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application number EP 85 40 1776

	DOCUMENTS COM	ISIDERED TO BE RELEVAN	T .]
Category	Citation of document	with indication, where appropriate, llevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CI.4)
	EP - A - 0 088	695 (CYTOGEN CORP.)		
	* Whole documen	t *	1-40,42	
	no. 3, March 198 American Associa Immunologists, G D. MEW et al.: ' therapy: treatme with tumor-speci	JS; 'Photoimmuno- ent of animal tumors		A 61 K 39/395
	* Whole document		1-7,9- 15,17- 39,42	
	20th January 197 abstract no. 150 Columbus, Ohio, W.T. SHEARER et with antibody-gl conjugates speci	US; al.: "Cytotoxicity ucose oxidase fic for a human and carcioembryonic		TECHNICAL FIELDS SEARCHED (Int. Cl.4)
NCOM	IPLETE SEARCH			A 61 K
at a mean alms sea aims not eason for ethodolimal	ingful search into the state of the a rched completely: rched incompletely: searched: the limitation of the search: for treatment body by surger	of the human or y or therapy e European Patent	mply with e to carry	
TH	Place of search IE HAGUE	Date of completion of the search 22-03-1988		Examiner SKELLY
docu techr	CATEGORY OF CITED DOCU cularly relevant if taken alone cularly relevant if combined with ment of the same category nological background written disclosure mediate document	E: earlier patent after the filing th another D: document cit L: document cit	nciple underlyi document, bu date ed in the appli ed for other re	ng the invention It published on, or



CLAIMS INCURRING FEES				
-				
_				
The	pres	ent European patent application comprised at the time of filing more than ten claims.		
		All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.		
[Only part of the claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid,		
		namely claims:		
[No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.		
77	L	ACK OF UNITY OF INVENTION		
X The		ch Division considers that the present European patent application does not comply with the requirement of unity of		
inver		and relates to several inventions or groups of inventions,		
	-	Claims 1-40: Antibody-therapeutic agent conjugates		
		Claim 42: Novel compound		
		Claim 43: Novel compound		
-				
;				
		•		
•		•		
		-		
•				
	X	All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.		
		Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid,		
		namely claims:		
·		None of the further search fees has been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims,		
		namely claims:		

PARTIAL EUROPEAN SEARCH REPORT

European Patent
Office

EP 85 40 1776 -2-

	DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF THE APPLICATION (Int. CI 4)	
ategory	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
	14(4), 539-47	8 16 40	-
	* Abstract *	8,16,40	
Υ,Υ	CHEMICAL ABSTRACTS, vol. 102, no. 15 15th April 1985, page 283, abstract no. 128005x, Columbus, Ohio, US; Ch.K. WAT et al.: "Photosensitizer- protein conjugates:potential use as photoimmunotherapeutc agents", & PROG.CLIN.BIOL.RES. 1984, 170 (Porphyrin localization treat tumors), 351-9	1_7 9_	
	* Abstract *	15,17-	TECHNICAL FIELDS SEARCHED (Int. CI.4)
P,Y	CHEMICAL ABSTRACTS, vol. 103, no. 15, 14th October 1985, page 558, abstract 121395m, Columbus, Ohio, US; D. MEW et al.: "Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation", & CANCER RES. 1985, 45(9), 4380-6		
	* Abstract *	1-40	
A	THE JOURNAL OF IMMUNOLOGY, vol. 125, no. 3, September 1980, page 1201, Williams & Wilkins Co. US; G.W. PHILPOTT et al.: "Selective binding and cytotoxicity of rat basophilic leukemia cells (RBL-1) with immunoglobulin E-biotin and avidin-glucose oxidase conjugates"		•
Y	CHEMICAL ABSTRACTS, vol. 89, no. 13, 25th September 1978, page 29, abstract no. 110773z Columbus, Ohio, US; & JP - A - 77 141 882 (E. HASEGAWA et al.) 26-1-1977		
	* Abstract *	42	·

PARTIAL EUROPEAN SEARCH REPORT

DOCUMENTS CONSIDERED TO BE RELEVANT	CLASSIFICATION OF THE APPLICATION (Int. Cl.4)	
Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
CHEMICAL ABSTRACTS, vol. 97, no. 7, 16th August 1982, page 224, abstract no. 51193a Columbus, Ohio, US; H. SAKURAI et al.: "Growth inhibition and photoxidative toxicity in the housefly. Musca domestica L.caused by xanthene dye in larval growth medium and after injection" & ENVIRON.ENTOMOL. 1982, 11(2), 467-70	4.2	
* Abstract *	43	
CANCER RESEARCH, vol. 45, September 1985, pages 4380-4386 D. MEW et al.: "Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation"		TECHNICAL FIELDS SEARCHED (Int CI.4)
* Whole document *	1-7, 9-15, 17-39	
CHEMICAL ABSTRACTS, vol. 103, no. 5 5th August 1985, page 491, abstract no. 37259n Columbus, Ohio, US; R. OCAMPO et al.: "Identification of polar porphyrins in oil shale" & J.CHEM.SOC.CHEM.COMMUN. 1985, (4), 198-200		•
* Abstract *	42	
	CHEMICAL ABSTRACTS, vol. 97, no. 7, 16th August 1982, page 224, abstract no. 51193a Columbus, Ohio, US; H. SAKURAI et al.: "Growth inhibition and photoxidative toxicity in the housefly. Musca domestica L.caused by xanthene dye in larval growth medium and after injection" & ENVIRON.ENTOMOL. 1982, 11(2), 467-70 * Abstract * CANCER RESEARCH, vol. 45, September 1985, pages 4380-4386 D. MEW et al.: "Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation" * Whole document * CHEMICAL ABSTRACTS, vol. 103, no. 5 5th August 1985, page 491, abstract no. 37259n Columbus, Ohio, US; R. OCAMPO et al.: "Identification of polar porphyrins in oil shale" & J.CHEM.SOC.CHEM.COMMUN. 1985, (4), 198-200	CHEMICAL ABSTRACTS, vol. 97, no. 7, 16th August 1982, page 224, abstract no. 51193a Columbus, Ohio, US; H. SAKURAI et al.: "Growth inhibition and photoxidative toxicity in the housefly. Musca domestica L.caused by xanthene dye in larval growth medium and after injection" & ENVIRON.ENTOMOL. 1982, 11(2), 467-70 * Abstract * CANCER RESEARCH, vol. 45, September 1985, pages 4380-4386 D. MEW et al.: "Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation" * Whole document * 1-7, 9-15, 17-39 CHEMICAL ABSTRACTS, vol. 103, no. 5, 5th August 1985, page 491, abstract no. 37259n Columbus, Ohio, US; R. OCAMPO et al.: "Identification of polar porphyrins in oil shale" & J.CHEM.SOC.CHEM.COMMUN. 1985, (4), 198-200